Leveratam Tablet contains Levetiracetam 500mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. It is commonly prescribed as adjunctive therapy but may also be used as monotherapy in certain cases. Leveratam is well-absorbed orally with rapid onset of action and exhibits linear pharmacokinetics, allowing for predictable dosing. The drug is primarily eliminated unchanged via renal excretion, necessitating dose adjustments in patients with renal impairment. Common adverse effects include somnolence, dizziness, fatigue, and behavioral changes such as irritability or mood swings; however, it is generally well-tolerated. Caution is advised in patients with a history of psychiatric disorders or suicidal ideation. Leveratam should be used under strict medical supervision, with regular monitoring for efficacy and adverse reactions. Abrupt discontinuation is discouraged to prevent seizure exacerbation. This medication is contraindicated in patients with known hypersensitivity to Levetiracetam or any of its excipients. Leveratam Tablet offers an effective and reliable option for seizure management in diverse patient populations.